BioNTech SE: BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

Fourth quarter and full year revenues of €5.5 billion1 and €19.0 billion1, respectivelyFull year net income of €10.3 billion and fully diluted earnings per share of €39.63 ($46.872)Expect to authorize

Related Keywords

Germany ,United States ,Wuhan ,Hubei ,China ,Spain ,Turkey ,Belgium ,American ,Sanofi Libtayo ,Fosun Pharma ,Sylke Maas ,Biontech Ribomabs ,Biontech Ribomab ,Jens Holstein ,Autogene Cevumeran ,Ugur Sahin ,Genentech ,Global Development Organization ,German Central Bank Deutsche Bundesbank ,Influenza Vaccine Program ,Melinda Gates Foundation ,Nasdaq ,Vaccine Program ,Development Expenses ,Pfizer ,Crescendo Biologics Ltd ,European Union ,Global External Communications ,Committee For Medicinal Products Human Use ,Shingles Vaccine Program ,Science Based Targets Initiative ,Drug Administration ,European Commission ,Data Monitoring Committee ,Malaria Vaccine Program ,Tuberculosis Vaccine Program ,American Association For Cancer Research ,Biontech Group ,Roche Group ,African Union ,University Of Pennsylvania ,Institutional Shareholder Services ,European Medicines Agency ,Annual General ,Fourth Quarter ,Full Year ,General Meeting ,Year Expenses ,Year Tax Assumptions ,Management Board ,Supervisory Board ,Annual General Meeting ,Administrative Expenses ,Cash Deposits ,Trade Receivables ,Annual Report ,German Central Bank ,Deutsche Bundesbank ,Independent Data Monitoring Committee ,Emergency Use Authorization ,Conditional Marketing Authorization ,Medicinal Products ,Human Use ,Infectious Disease ,Fast Track Designation ,Orphan Drug Designation ,Natural Killer ,American Association ,Cancer Research ,Early Warning System ,Crescendo Biologics ,Sustainability Report ,Investor Relations ,United Nations Global ,For Scope ,Capital Markets Day ,New Technologies ,Private Securities Litigation Reform Act ,Biontech ,Nnounces ,Fourth ,Quarter ,Bull ,Ear ,021 ,Financial ,Results ,Corporate ,Update ,